New hope for relapsed blood cancer: Three-Drug combo enters trials
NCT ID NCT07601607
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of three drugs (lisaftoclax, chidamide, and rituximab) in adults with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to find a safe and effective dose and see if the combination can shrink tumors. About 51 participants will take part in this early-phase trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun yat-sen university cancer center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.